IgA nephropathy is a primary glomerular disease characterized by mesangial deposition of immunoglobulin A in the kidneys, causing hematuria, proteinuria, and variable progression to chronic kidney disease. Clinical course is heterogeneous, ranging from stable kidney function to progressive renal failure. It is one of the most common primary glomerulopathies worldwide.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.
The FDA granted full approval to Filspari to reduce proteinuria in patients aged eight and older with FSGS without nephrotic syndrome. The decision was based on Phase III DUPLEX data versus irbesartan.
Final phase 3 trial results show atrasentan (Vanrafia®) provides significant long-term kidney function benefits in IgA nephropathy patients, with a 2.59 mL/min/1.73m² eGFR improvement versus placebo. Earlier phase 2 data demonstrated the drug reduces proteinuria by 30.7% when added to standard background therapy. The drug's manufacturer plans to seek traditional FDA approval in 2026 based on these findings.
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
Novartis announced positive Phase III ALIGN results for Vanrafia in IgA nephropathy and plans to build a new radioligand therapy manufacturing site in Denton, Texas, operational by 2028.
Novartis announced final Phase III ALIGN trial results showing Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy, with a 2.39ml/min/1.73m² eGFR difference versus placebo at week 136.
Novartis US shares traded at all-time highs in early February 2026 despite expected generic competition, driven by sales above expectations and positive Phase 3 kidney drug data. The company's market capitalization reached $265.2 billion.
Novartis announced final Phase III ALIGN results showing Vanrafia slowed kidney function decline in adults with IgA nephropathy, supporting planned submissions for traditional approval in 2026 following accelerated approvals in the U.S. and China in 2025.
The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07541287 |
A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07498335 |
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN |
NOT_YET_RECRUITING | PHASE3 |
| NCT07481084 |
IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection |
NOT_YET_RECRUITING | |
| NCT07319585 |
Managed Access Programs for EXV811, Atrasentan |
AVAILABLE | |
| NCT07054684 |
Study of BHV-1400 in IgA Nephropathy |
RECRUITING | PHASE1 |
| NCT07035665 |
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT07030894 |
Nefecon and Ambrisentan in IgA Nephropathy |
RECRUITING | PHASE4 |
| NCT07010250 |
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis |
NOT_YET_RECRUITING | |
| NCT06830395 |
Study of CM313 in Subject With IgA Nephropathy |
NOT_YET_RECRUITING | PHASE2 |
| NCT06774664 |
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
